Chau Khoung

Chau Q. Khuong is a seasoned healthcare investor and entrepreneur with over two decades of experience investing in private and public biotechnology and medical device companies. He currently manages investments through CJNV BioVentures, a life sciences investment firm he founded in 2022 to provide capital solutions and strategic advisory to biotech and medtech entrepreneurs at the earliest stages of company formation.

From 2003 to 2021, Mr. Khuong worked at OrbiMed Advisors, a global healthcare-focused investment firm, where he was a Partner and member of the investment committee directing capital deployment from OrbiMed's flagship venture capital funds. Over his investment career, he has been an active lead investor in drug development and medical device companies across all stages and therapeutic areas, including oncology, infectious diseases, ophthalmology, gene therapy, and gene editing. These investments have resulted in thirteen FDA-approved therapeutics or devices.

Mr. Khuong has served on the boards of directors of more than two dozen biotech and medical device companies, including Arius Research (acquired by Roche in 2008 for $189 million); Bellus Health (acquired by GSK in 2023 for $2 billion); Cerexa Pharmaceuticals (acquired by Forest in 2006 for $480 million plus a $100 million earnout); Durata Pharmaceuticals (acquired by Actavis in 2014 for $675 million); Fusion Pharmaceuticals (acquired by AstraZeneca in 2024 for $2.4 billion); Glaukos Medical (NYSE: GKOS, $9.92 billion market cap as of 9/14/2026); Inspire Medsystems (NYSE: INSP, $2.12 billion market cap as of 9/14/2026); Intellia (NASDAQ: NTLA, $1.67 billion market cap as of 9/14/2026); Intercept Pharma (NASDAQ: ICPT, 2012–2023); Noctrix Health (acquired by ResMed in 2026 for $340 million); Peninsula Pharma (acquired by J&J in 2005 for $245 million); Perfuse Therapeutics (acquired by Bayer in 2026 for up to $2.45 billion); Rempex (acquired by The Medicines Company for up to $460 million); and ReViral Ltd (acquired by Pfizer for up to $525 million).

Mr. Khuong is a seed-round investor and, since 2023, has been Chairman of OnCusp Therapeutics, a cancer therapeutics company that raised $100 million in 2023 from leading healthcare investors including Novo Ventures, F-Prime, and OrbiMed. Since 2024, he has been a Director of Restora, developer of novel neurostimulation device technology to treat obstructive sleep apnea. Since 2025, he has been lead investor and board director of Vidya Therapeutics, developing novel treatments for inflammatory and autoimmune diseases. Since 2026, he has been a board director at Steer Bio, developing a first-in-class disease-modifying treatment for lymphedema patients. Mr. Khuong also serves as a Director (2016–present) of the Alliance for Cancer Cell and Gene Therapy (ACGT), a pioneering nonprofit founded in 2000 dedicated to supporting research in adoptive cell therapy, CAR-T, and oncolytic virotherapy to treat underserved malignancies.

Mr. Khuong studied at Yale University, where he earned a B.S. in Molecular Biology and an MPH in Infectious Disease Epidemiology.